Cancer News, Treatment and Research

In Australia, 20000 new cases of prostate cancer are diagnosed each year, and 3000 men die from the disease annually. If detected early, prostate cancer can be treated with surgery and/or radiotherapy. But when the cancer has spread, treatment options are limited. There is an urgent need for new molecular targets for late stage treatments. Eph and ephrin proteins are already know to play a role in cancers like leukaemia, glioma and ovarian cancer and clinical trials targeting the Eph protein EphA3 in leukaemia are underway. This research team will use their Rio Tinto Ride to Conquer Cancer grant to further investigate the role of these proteins in late stage prostate cancer, with a long-term view to developing new targets and treatments.